Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Comfort Systems USA Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Comfort Systems USA Inc trades at $1,720 (market cap $61.82B). The key difference: Comfort Systems USA Inc is the larger of the two by market cap, and Comfort Systems USA Inc pays a 0.15% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FIX | |
|---|---|---|
Market Cap | $39.89B | $61.82B |
Sector | Health | Technology |
52-Week High | $491.22 | $2.07K |
52-Week Low | $278.09 | $532.14 |
Enterprise Value | $38.15B | $61.11B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Comfort Systems USA (FIX) trades at $1,756.09, down 1.42% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with consistent earnings beats, robust revenue growth to $10.1B in 2026, and high profitability margins. Recent news highlights expansion in modular capabilities and leadership transitions, while analyst consensus remains bullish with a $2,100 price target.
Outlook is positive driven by AI infrastructure demand and a record backlog, though premium valuation multiples pose a risk. Execution of growth initiatives and macroeconomic conditions are key watchpoints for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
